We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Amgevita

News List

NHS England set to save 300 million pounds per year after reaching deals on Humira biosimilars firstwordpharma
November 27, 2018
NHS England said Monday that it negotiated deals with drugmakers on biosimilar versions of AbbVie's Humira (adalimumab), potentially leading to annual savings of 300 million pounds
Orion and Amgen to collaborate on the commercialisation of AMGEVITA (biosimilar adalimumab) in Finland October 25, 2018
Orion and Amgen to collaborate on the commercialisation of AMGEVITA (biosimilar adalimumab) in Finland
Amgen launches first biosimilar of best-selling Humira in Europe pharmatimes
October 19, 2018
Amgen has announced the launch of a proprietary biosimilar version of Abbvie's best-selling drug Humira (adalimumab) across all European markets, beginning 16 October.
Amgen begins rolling out Humira biosimilar in the EU pharmatimes
October 19, 2018
Amgen has begun launching Amgevita, the first biosimilar of AbbVie’s anti-inflammatory blockbuster Humira to win approval in Europe, across the region.